MU
Manuel Uth
· 1 min read
BusinessThe Decoder
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
Original source
This story was published by The Decoder and written by Manuel Uth. SyncAI.news shows a preview; the complete article is on the publisher's site.
Read the full story on the-decoder.com
